正念认知疗法作为NHS谈话治疗未缓解抑郁症的后续治疗:英国随机对照优效性试验
该研究在英國三个地区开展平行随机对照优效性试验,纳入234例经NHS谈话治疗高强度心理治疗后未缓解(PHQ-9≥10)的抑郁症患者,比较正念认知疗法(MBCT)联合常规治疗与单独常规治疗。
要点
- MBCT联合常规治疗可显著改善NHS谈话治疗未缓解抑郁症患者的抑郁症状。
核心结论
- 对于NHS谈话治疗高强度心理治疗后未缓解的抑郁症患者,MBCT联合常规治疗在34周时显著降低抑郁症状且具有成本效果。
- 研究支持将MBCT作为心理治疗未缓解后的后续治疗选择。
研究设计与样本
- 平行、随机、对照、优效性试验,在英国Devon、London和Sussex三个地区开展。
- 纳入234例当前重性抑郁障碍且经≥12次NHS谈话治疗高强度心理治疗后未缓解(PHQ-9≥10)的患者。
- 按1:1随机分配至MBCT联合常规治疗(118例)或单独常规治疗(116例),按抑郁严重度、基线抗抑郁药使用和招募地点进行最小化。
- MBCT通过视频会议进行,包括1次个体定向会话和8次每周团体会话。
- 主要临床结局为随机化后34周PHQ-9抑郁症状减少,在意向性治疗人群中采用观察数据进行分析。
主要发现
- Bootstrap平均成本与QALY差异显示,对于决策者愿意支付的任何QALY改善值,MBCT联合常规治疗有91%的概率更便宜且更有效。
- 未观察到试验或治疗相关的严重不良事件,也无其他伤害证据。
关键数值与推荐
- 未缓解定义:经足够剂量NHS谈话治疗高强度心理治疗(≥12次会话)后PHQ-9评分≥10。
临床怎么用
- 对于NHS谈话治疗高强度心理治疗后未缓解的抑郁症患者,可考虑提供MBCT作为后续治疗。
- MBCT为可扩展的团体干预,可通过视频会议交付,适合在常规护理环境中实施。
- 临床决策时可参考MBCT在改善抑郁症状和成本效果方面的证据。
局限性
- 主要结局分析仅使用观察数据,未对缺失数据进行插补。
- 样本以女性(71%)和White(86%)为主,可能限制普适性。
- 研究在英国三个地区开展,其他医疗体系的外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-remission after psychological therapy for major depressive disorder is common, yet there are no established further-line treatments. In the UK National Health Service (NHS) Talking Therapies programme, about 50% of patients with depression who come to the end of the stepped care pathway do not show remission of symptoms. We aimed to investigate whether mindfulness-based cognitive therapy (MBCT) can improve clinical outcomes and whether the additional financial cost is worthwhile. METHODS: We conducted a parallel, randomised, controlled, superiority trial in three sites in the UK (Devon, London, and Sussex). Patients with current major depressive disorder whose symptoms had not reached remission (assessed as Patient Health Questionnaire-9 [PHQ-9] score ≥10) after an adequate dose of NHS Talking Therapies high-intensity therapy (≥12 sessions) were recruited from 20 NHS Talking Therapies services. Participants were allocated through remote random assignment (1:1) to MBCT plus treatment as usual or treatment as usual alone at the UK Clinical Research Collaboration-registered Exeter Clinical Trials Unit with minimisation on depression severity (PHQ-9 score <19 vs ≥19), antidepressant use at baseline (yes vs no), and recruitment site (Devon vs London vs Sussex). MBCT was delivered via videoconference and comprised an individual orientation session and eight weekly group sessions. The primary clinical outcome was reduction in depression symptomatology at 34 weeks after randomisation, using the PHQ-9. Cost-effectiveness was evaluated in terms of costs to primary, secondary, and tertiary health and social care services collected using the Adult Service Use Schedule and quality-adjusted life-years (QALYs) via health utilities derived from the EQ-5D. Primary outcome analyses were masked in the intention-to-treat population using observed data only. Lived experience experts were integral to all stages of this research. The trial was prospectively registered with ISRCTN, ISRCTN17755571. FINDINGS: Between April 20, 2021, and Jan 24, 2023, we enrolled 234 eligible participants, 166 (71%) of whom identified as women, 65 (28%) as men, one (<1%) as other, and two (1%) preferred not to say. The mean age was 42·5 years (SD 13·9). 201 (86%) of 234 participants were White. 118 participants were assigned to MBCT plus treatment as usual and 116 to treatment as usual alone, 101 and 102 of whom completed the final follow-up, respectively. At 34 weeks after randomisation, the MBCT plus treatment as usual group had significantly lower levels of depression symptomatology than the treatment as usual alone group (adjusted between-group difference -2·49, 95% CI -3·89 to -1·09; p=0·0006; Cohen's d -0·41, 95% CI -0·67 to -0·15). Utility scores were higher and costs were lower in the MBCT group (adjusted mean cost difference -£245·23, 95% CI -581·92 to 91·46; p=0·15) over the course of the study. The MBCT plus treatment as usual group had an estimated 99% chance of being cost-effective at the £20 000 per QALY threshold. Bootstrapped mean differences in costs and QALYs indicated a 91% probability of MBCT plus treatment as usual being less costly and more effective than treatment as usual alone for all values a decision maker might be willing to pay for an improvement in QALYs. We observed no trial or treatment-related serious adverse events and no other evidence of harms. INTERPRETATION: Our findings show that mindfulness-based treatment can be beneficial after non-remission from major depressive disorder following psychological, stepped care treatments. Together with evidence from previous studies of non-remission after pharmacological treatment, our findings establish MBCT, an easily scalable group-based intervention, as a further-line treatment. Implementation of MBCT for patients who continue to have major depressive disorder in routine care settings (NHS Talking Therapies and beyond) is warranted. FUNDING: UK National Institute for Health and Care Research Research for Patient Benefit programme.
引用
- Barnhofer T, Dunn BD, Strauss C, et al. Mindfulness-based cognitive therapy versus treatment as usual after non-remission with NHS Talking Therapies high-intensity psychological therapy for depression: a UK-based clinical effectiveness and cost-effectiveness randomised, controlled, superiority trial. Lancet Psychiatry. 2025. PMID: 40379363. doi:10.1016/S2215-0366(25)00105-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。